GlassScriptPhysician profile
William T Cox
NPI 1184717936
$8,208.41
in general payments reported to CMS, 2019-2025
34 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,224 · 2020: $980 · 2021: $967 · 2022: $1,254 · 2023: $917 · 2024: $1,432 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,614 · Education: $170.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,613.96 |
| Education | $169.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,222.04 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Bayer Healthcare Pharmaceuticals INC. | $620.72 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $489.06 | 2022-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $423.82 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Glaxosmithkline, LLC. | $396.42 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $348.32 | 2020-2025 | |
| Amgen INC. | $334.87 | 2019-2024 | Repatha, Otezla |
| Novo Nordisk INC | $260.59 | 2019-2024 | Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $213.15 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $207.93 | 2019-2023 | Jardiance |
| Abbvie INC. | $204.42 | 2022-2024 | Viberzi, Linzess |
| Novartis Pharmaceuticals Corporation | $193.92 | 2019-2025 | |
| Astellas Pharma US INC | $169.99 | 2024 | |
| Allergan, INC. | $108.07 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $107.83 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $105.39 | 2020-2024 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $91.94 | 2024 | Austedo Xr |
| Dexcom, INC. | $90.82 | 2024-2025 | Dexcom G6 Transmitter |
| Merck Sharp & Dohme LLC | $90.68 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $71.33 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $69.83 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $56.42 | 2023-2025 | Zoryve, Livalo, Seglentis |
| Lilly USA, LLC | $50.58 | 2019-2021 | |
| Abbott Laboratories | $49.20 | 2023 | Freestyle Libre 3 |
| Exact Sciences Corporation | $40.67 | 2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Sanofi Pasteur INC. | $31.68 | 2022-2024 | |
| Janssen Biotech, INC. | $30.88 | 2019 | |
| Inspire Medical Systems, INC. | $23.81 | 2025 | Inspire |
| Amarin Pharma, INC. | $20.43 | 2020 | |
| Axsome Therapeutics, INC. | $20.24 | 2024 | Auvelity |
| Zyla Life Sciences, INC. | $17.08 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.93 | 2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $15.94 | 2020 | |
| Radius Health, INC. | $13.41 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Cox listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.